FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023661149> ?p ?o ?g. }

• W2023661149 endingPage "1928" @default.
• W2023661149 startingPage "1925" @default.
• W2023661149 abstract "The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma. The initial report demonstrated non-inferior efficacy with subcutaneous versus intravenous bortezomib for the primary end point: overall response rate after four cycles of single-agent bortezomib. We report updated outcome analyses after prolonged follow up. Best response rate (after up to ten cycles of bortezomib ± dexamethasone) remained 52% in each arm, including 23% and 22% complete or near-complete responses with subcutaneous and intravenous bortezomib, respectively. Time to progression (median 9.7 vs. 9.6 months; hazard ratio 0.872, P=0.462), progression-free survival (median 9.3 vs. 8.4 months; hazard ratio 0.846, P=0.319), and overall survival (1-year: 76.4% vs. 78.0%, P=0.788) were comparable with subcutaneous versus intravenous bortezomib. Peripheral neuropathy rates remained significantly lower with subcutaneous versus intravenous bortezomib, with increased rates of improvement/resolution at the time of this analysis." @default.
• W2023661149 created "2016-06-24" @default.
• W2023661149 creator A5011827756 @default.
• W2023661149 creator A5012217797 @default.
• W2023661149 creator A5016941619 @default.
• W2023661149 creator A5019718106 @default.
• W2023661149 creator A5040411677 @default.
• W2023661149 creator A5048560248 @default.
• W2023661149 creator A5049970120 @default.
• W2023661149 creator A5054647485 @default.
• W2023661149 creator A5062322697 @default.
• W2023661149 creator A5087353636 @default.
• W2023661149 date "2012-06-11" @default.
• W2023661149 modified "2023-10-17" @default.
• W2023661149 title "Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma" @default.
• W2023661149 cites W1503165851 @default.
• W2023661149 cites W173435793 @default.
• W2023661149 cites W1952760452 @default.
• W2023661149 cites W1978377409 @default.
• W2023661149 cites W1989740966 @default.
• W2023661149 cites W2044436186 @default.
• W2023661149 cites W2055338149 @default.
• W2023661149 cites W2070790769 @default.
• W2023661149 cites W2096207943 @default.
• W2023661149 cites W2103289287 @default.
• W2023661149 cites W2108235071 @default.
• W2023661149 cites W2120474651 @default.
• W2023661149 cites W2120780398 @default.
• W2023661149 cites W2134902298 @default.
• W2023661149 cites W2151595053 @default.
• W2023661149 cites W2169183166 @default.
• W2023661149 cites W2171626043 @default.
• W2023661149 cites W2478829584 @default.
• W2023661149 doi "https://doi.org/10.3324/haematol.2012.067793" @default.
• W2023661149 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3685287" @default.
• W2023661149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22689676" @default.
• W2023661149 hasPublicationYear "2012" @default.
• W2023661149 type Work @default.
• W2023661149 sameAs 2023661149 @default.
• W2023661149 citedByCount "118" @default.
• W2023661149 countsByYear W20236611492012 @default.
• W2023661149 countsByYear W20236611492013 @default.
• W2023661149 countsByYear W20236611492014 @default.
• W2023661149 countsByYear W20236611492015 @default.
• W2023661149 countsByYear W20236611492016 @default.
• W2023661149 countsByYear W20236611492017 @default.
• W2023661149 countsByYear W20236611492018 @default.
• W2023661149 countsByYear W20236611492019 @default.
• W2023661149 countsByYear W20236611492020 @default.
• W2023661149 countsByYear W20236611492021 @default.
• W2023661149 countsByYear W20236611492022 @default.
• W2023661149 countsByYear W20236611492023 @default.
• W2023661149 crossrefType "journal-article" @default.
• W2023661149 hasAuthorship W2023661149A5011827756 @default.
• W2023661149 hasAuthorship W2023661149A5012217797 @default.
• W2023661149 hasAuthorship W2023661149A5016941619 @default.
• W2023661149 hasAuthorship W2023661149A5019718106 @default.
• W2023661149 hasAuthorship W2023661149A5040411677 @default.
• W2023661149 hasAuthorship W2023661149A5048560248 @default.
• W2023661149 hasAuthorship W2023661149A5049970120 @default.
• W2023661149 hasAuthorship W2023661149A5054647485 @default.
• W2023661149 hasAuthorship W2023661149A5062322697 @default.
• W2023661149 hasAuthorship W2023661149A5087353636 @default.
• W2023661149 hasBestOaLocation W20236611491 @default.
• W2023661149 hasConcept C126322002 @default.
• W2023661149 hasConcept C126894567 @default.
• W2023661149 hasConcept C141071460 @default.
• W2023661149 hasConcept C143998085 @default.
• W2023661149 hasConcept C168563851 @default.
• W2023661149 hasConcept C203092338 @default.
• W2023661149 hasConcept C207103383 @default.
• W2023661149 hasConcept C2776364478 @default.
• W2023661149 hasConcept C2776390293 @default.
• W2023661149 hasConcept C2777478702 @default.
• W2023661149 hasConcept C2778367456 @default.
• W2023661149 hasConcept C2780401358 @default.
• W2023661149 hasConcept C44249647 @default.
• W2023661149 hasConcept C71924100 @default.
• W2023661149 hasConceptScore W2023661149C126322002 @default.
• W2023661149 hasConceptScore W2023661149C126894567 @default.
• W2023661149 hasConceptScore W2023661149C141071460 @default.
• W2023661149 hasConceptScore W2023661149C143998085 @default.
• W2023661149 hasConceptScore W2023661149C168563851 @default.
• W2023661149 hasConceptScore W2023661149C203092338 @default.
• W2023661149 hasConceptScore W2023661149C207103383 @default.
• W2023661149 hasConceptScore W2023661149C2776364478 @default.
• W2023661149 hasConceptScore W2023661149C2776390293 @default.
• W2023661149 hasConceptScore W2023661149C2777478702 @default.
• W2023661149 hasConceptScore W2023661149C2778367456 @default.
• W2023661149 hasConceptScore W2023661149C2780401358 @default.
• W2023661149 hasConceptScore W2023661149C44249647 @default.
• W2023661149 hasConceptScore W2023661149C71924100 @default.
• W2023661149 hasIssue "12" @default.
• W2023661149 hasLocation W20236611491 @default.
• W2023661149 hasLocation W20236611492 @default.
• W2023661149 hasLocation W20236611493 @default.
• W2023661149 hasLocation W20236611494 @default.
• W2023661149 hasOpenAccess W2023661149 @default.

• next